Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27688003 | 0.86 | CCR2 (0.64) | CCR2KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5266373 | 0.85 | CCR2 (0.65) | CCR2KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5266659 | 0.85 | CCR2 (0.70) | CCR2KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5342547 | 0.84 | CCR2 (0.69) | CCR2KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5947004 | 0.84 | CCR2 (0.67) | CCR2HTR2CADRB2KDM4EBRD4 | |
| SCHEMBL7700871 | 0.82 | HTR2C (0.64) | CCR2HTR2CADRB2KDM4EBRD4 | |
| SCHEMBL5331458 | 0.82 | HTR2C (0.57) | CCR2HTR2CADRB2KDM4EBRD4 | |
| SCHEMBL5946890 | 0.81 | CCR2 (0.71) | CCR2HTR2CADRB2 | |
| SCHEMBL5326779 | 0.80 | KMT2A (0.65) | HTR2CADRB2KDM4EBRD4ALDH1A1 | |
| SCHEMBL5946924 | 0.79 | CCR2 (0.63) | CCR2KDM4EBRD4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101065374-A | Substituted dipiperidine chemoattractant cytokine receptor 2 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-31 | — | — | CN | disclosed |
| EP-1802602-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006036527-A1 | SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069123-A1 | Substituted dipiperidine CCR2 antagonists | CCR2, CCR1, CCR5 | CCR2 1/4885HTR2C 1534/4885ADRB2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.